As of the latest Form 4 filed Jun 10, 2026.
What Collegium Pharmaceutical Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 41 most recent filings for COLL.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-10 | 2026-06-08 | SANTINI GINO Director | MExercise | +8.70K | $16.49 | $143K | No | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Freund John Gordon Director | SSale | −20.00 | $34.05 | $681.00 | No | Form 4 ↗ |
| 2026-05-18 | 2026-05-15 | Freund John Gordon Director | SSale | −4.13K | $34.54 | $143K | No | Form 4 ↗ |
| 2026-05-18 | 2026-05-15 | Freund John Gordon, Director | MExercise | +8.70K | $16.49 | $143K | No | Form 4 ↗ |
| 2026-05-18 | 2026-05-14 | Glancy Donovan Michael Director | AAward | +17.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-18 | 2026-05-14 | Balice-Gordon Rita J. Director | AAward | +8.74K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-18 | 2026-05-14 | Paya Carlos V Director | AAward | +8.74K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-18 | 2026-05-14 | Lurker Nancy Director | AAward | +8.74K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-18 | 2026-05-14 | Freund John Gordon Director | AAward | +8.74K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-18 | 2026-05-14 | SANTINI GINO Director | AAward | +8.74K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-18 | 2026-05-14 | BOHLIN GAREN G Director | AAward | +8.74K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-15 | 2026-05-13 | Lurker Nancy Director | SSale | −4.50K | $35.97 | $162K | No | Form 4 ↗ |
| 2026-05-13 | 2026-05-11 | BOHLIN GAREN G Director | SSale | −8.70K | $37.18 | $323K | No | Form 4 ↗ |
| 2026-05-13 | 2026-05-11 | BOHLIN GAREN G, Director | MExercise | +8.70K | $16.49 | $143K | No | Form 4 ↗ |
| 2026-04-03 | 2026-03-17 | Dieter David EVP & General Counsel | FTax | −8.84K | $35.72 | $316K | No | Form 4 ↗ |
| 2026-03-20 | 2026-03-18 | Dieter David EVP & General Counsel | SSale | −14.0K | $34.92 | $488K | Yes (planned) | Form 4 ↗ |
| 2026-03-11 | 2026-03-09 | Dieter David EVP & General Counsel | SSale | −6.22K | $36.65 | $228K | Yes (planned) | Form 4 ↗ |
| 2026-03-05 | 2026-03-03 | Dreyer Scott EVP & Chief Commercial Officer | SSale | −3.56K | $40.99 | $146K | Yes (planned) | Form 4 ↗ |
| 2026-03-05 | 2026-03-03 | Dreyer Scott, EVP & Chief Commercial Officer | SSale | −46.4K | $40.36 | $1.87M | Yes (planned) | Form 4 ↗ |
| 2026-02-12 | 2026-02-10 | Dieter David EVP & General Counsel | FTax | −2.78K | $46.75 | $130K | No | Form 4 ↗ |
| 2026-02-12 | 2026-02-10 | Dieter David, EVP & General Counsel | AAward | +9.01K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-12 | 2026-02-10 | Dieter David, EVP & General Counsel | AAward | +22.2K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-12 | 2026-02-10 | Tupper Colleen EVP & Chief Financial Officer | FTax | −26.7K | $46.75 | $1.25M | No | Form 4 ↗ |
| 2026-02-12 | 2026-02-10 | Tupper Colleen, EVP & Chief Financial Officer | FTax | −11.9K | $46.75 | $555K | No | Form 4 ↗ |
| 2026-02-12 | 2026-02-10 | Tupper Colleen, EVP & Chief Financial Officer | AAward | +32.7K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-12 | 2026-02-10 | Tupper Colleen, EVP & Chief Financial Officer | AAward | +26.4K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-12 | 2026-02-10 | Smith Thomas B EVP and Chief Medical Officer | FTax | −11.5K | $46.75 | $539K | No | Form 4 ↗ |
| 2026-02-12 | 2026-02-10 | Smith Thomas B, EVP and Chief Medical Officer | FTax | −5.90K | $46.75 | $276K | No | Form 4 ↗ |
| 2026-02-12 | 2026-02-10 | Smith Thomas B, EVP and Chief Medical Officer | AAward | +22.8K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-12 | 2026-02-10 | Smith Thomas B, EVP and Chief Medical Officer | AAward | +14.3K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-12 | 2026-02-10 | Dreyer Scott EVP & Chief Commercial Officer | FTax | −21.6K | $46.75 | $1.01M | No | Form 4 ↗ |
| 2026-02-12 | 2026-02-10 | Dreyer Scott, EVP & Chief Commercial Officer | FTax | −9.98K | $46.75 | $466K | No | Form 4 ↗ |
| 2026-02-12 | 2026-02-10 | Dreyer Scott, EVP & Chief Commercial Officer | AAward | +30.7K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-12 | 2026-02-10 | Dreyer Scott, EVP & Chief Commercial Officer | AAward | +19.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-12 | 2026-02-10 | Karnani Vikram President and CEO | FTax | −11.3K | $46.75 | $528K | No | Form 4 ↗ |
| 2026-02-12 | 2026-02-10 | Karnani Vikram, President and CEO | AAward | +32.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-12 | 2026-02-10 | Karnani Vikram, President and CEO | AAward | +79.3K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-12-10 | 2025-12-08 | Dreyer Scott EVP & Chief Commercial Officer | SSale | −6.47K | $48.66 | $315K | Yes (planned) | Form 4 ↗ |
| 2025-12-10 | 2025-12-08 | Dreyer Scott, EVP & Chief Commercial Officer | SSale | −11.1K | $47.89 | $533K | Yes (planned) | Form 4 ↗ |
| 2025-12-10 | 2025-12-08 | Dreyer Scott, EVP & Chief Commercial Officer | MExercise | +17.6K | $15.90 | $280K | Yes (planned) | Form 4 ↗ |
| 2025-12-09 | 2025-12-05 | Balice-Gordon Rita J. Director | SSale | −3.65K | $47.03 | $172K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also COLL’s full analysis or the market-wide insider trading feed. The tabs above jump to COLL’s other SEC data.
Source: SEC Form 4 filings for COLL, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.